ABSTRACT
Objective To explore the expression of FOXM1 in non-small cell lung cancer(NSCLC) and the relationship between FOXM1 expression and the clinical pathological factors,clinical response to target-therapy in NSCLC remained unknown.Methods A total of 80 NSCLC patients were recruited into this study,FOXM1 expression was assessed by immunohistochemistry and analyzed with the clinical pathological factors and clinical response to target-therapy.Results The positive rate of FOXM1 expression was 41.25%.The positive expression of FOXM1 had no significant difference in patients with different age,gender,cancer staging,smoking history(P>0.05),but had significant difference in patients with different degree of differentiation,lymph node metastasis(P<0.05).Survival time in patients with positive FOXM1 expression was significant shorter than that with negative FOXM1 expression(P<0.05).Conclusion The expression of FOXM1 closely correlated with patients histological differentiation,lymph node metastasis,progress-free survival time in patients with positive FOXM1 expression was significantly shorter than those with negative FOXM1 expression.
